- Conditions
- Early Alzheimer's Disease
- Interventions
- Semagludtide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 1,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 96
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 76 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer's Disease (AD)
- Interventions
- VY7523, Placebo Comparator
- Drug
- Lead sponsor
- Voyager Therapeutics
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 14 more
- Conditions
- Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, TBI (Traumatic Brain Injury), Aging, Healthy Elderly, Alzheimer&Amp;Amp;#39;s Dementia (AD)
- Interventions
- Mindfulness Intervention, Waitlist then mindfulness
- Behavioral
- Lead sponsor
- VA Boston Healthcare System
- Federal
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Early Alzheimer´s Disease
- Interventions
- Semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 1,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 107
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 85 more
- Conditions
- Alzheimer Disease (AD)
- Interventions
- Protollin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Mild Dementia
- Interventions
- repetitive transcranial magnetic stimulation (rTMS), sham repetitive transcranial magnetic stimulation rTMS
- Device · Other
- Lead sponsor
- Chi-Ying (Roy) Lin
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer´s Disease
- Interventions
- Lanabecestat, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 2,218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 77
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 58 more
- Conditions
- Alzheimer's Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 60 Years and older
- Enrollment
- 2,850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland